Arcturus Therapeutics Holdings Inc. (ARCT) · Aug 25, 2026 · Other events
No new info — Poster notice confirms an expected presentation; additional data and regulatory plan remain due later this quarter
Arcturus will present ARCT-810 OTC-deficiency data at SSIEM, but the filing adds no results; fuller data and a regulatory plan remain pending.
The market was already expecting an ARCT-810 update this quarter. Arcturus said on August 6, 2026 that Phase 2 enrollment and dosing were complete, with data and a regulatory plan expected in the third quarter, so this scheduled poster is confirmation rather than a surprise.
The filing announces a presentation, not a clinical result. Arcturus says it will present a poster on the therapy’s impact on dietary intake and biochemical data in adolescents and adults with OTC deficiency. 〔0〕 The supplied filing provides no efficacy, safety, biomarker, or regulatory numbers to change the investment case.
The actual catalyst remains the later-quarter data and regulatory update. The filing explicitly defers both items: 〔1〕 Against the standing expectation, today’s 8-K adds timing and venue—but no new information—making the appropriate read neutral.
ARCT-810 data and regulatory plan, later this quarter
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!